Phase 2 MILESTONE results suggest that postinduction minimal residual disease (MRD) negativity can identify a small subset of transplant-eligible patients with newly diagnosed multiple myeloma who may defer autologous stem cell transplantation.
|Videos|November 5, 2021
Overview: Mechanisms of Potassium Handling in CKD
Boyd gave a general overview of how potassium handling works in chronic kidney disease, specifically with hyperkalemia.
Advertisement
Pharmacy Times spoke to Dr. Cary Boyd-Shiwarski about her session at the ASN 2021 conference titled "Mechanisms of Potassium Handling in CKD."
Boyd gave a general overview of how potassium handling works in chronic kidney disease, specifically with hyperkalemia.
Advertisement
Related to this article
Long-term CASSIOPEIA Registry results show that daratumumab maintenance supports sustained minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma.
FDA clears tiratricol for MCT8 deficiency, lowering dangerous T3 and outlining dosing, lab testing, and pharmacy access.
A single infusion reversed new-onset type 1 diabetes (T1D) in more than half of treated mice by strengthening regulatory T cells and driving autoreactive CD8+ T cells into a less destructive state.
Approval spans early and levodopa-treated disease; a 6-week titration and CYP3A interactions put pharmacists at the center of starting therapy.
In a Pharmacy Times interview, study coauthor William J. Peppard, PharmD, discusses the association between suzetrigine and fewer opioid refills after knee replacement, the limits of the evidence, and the access barriers pharmacists can help patients navigate.
The once-daily tablet is the third approved treatment for fibrodysplasia ossificans progressiva (FOP), with CYP3A4 and metformin interaction guidance.
Marissa Reigelman of US Pharmacopeia explains how single-country dependence on key starting materials, combined with low prices, has kept 5 critical injectable drugs in shortage for more than a decade.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Tavapadon, First D1/D5 Agonist for Parkinson Disease
2
CagriSema Tops Tirzepatide 5 mg for Weight Loss in REIMAGINE 5
3
CKD Prevalence Unmoved Despite Billions in Virtual Care
4
Engineered Stem Cell Therapy Reverses New-Onset T1D in Mice by Reprogramming T Cells
5